Overview

A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia

Status:
NOT_YET_RECRUITING

Trial end date:
2031-08-31

Target enrollment:

Participant gender:

Summary

To learn about the safety and effects of revumenib in combination with blinatumomab in patients with newly diagnosed or relapsed/refractory Ph-negative ALL with a KMT2A rearrangement.

Phase:

PHASE1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

Amgen
Syndax Pharmaceuticals

Treatments:

blinatumomab
revumenib